Literature DB >> 19890966

Inflammatory myofibroblastic tumor of the conjunctiva: response to chemotherapy with low-dose methotrexate and vinorelbine.

Francesca Favini1, Antonio Giordano Resti, Paola Collini, Michela Casanova, Cristina Meazza, Giovanna Trecate, Andrea Ferrari.   

Abstract

Inflammatory myofibroblastic tumor (IMT) is an unusual entity that mainly affects children and young adults, and for which standardized therapies for inoperable cases are still lacking. We report on a 12-year-old patient with an extremely rare and inoperable conjunctival location that was treated with chemotherapy using low-dose methotrexate plus vinorelbine, achieving complete tumor remission. This regimen is usually well tolerated and may be considered as the treatment of choice for cases of unresectable advanced IMT. Copyright 2009 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19890966     DOI: 10.1002/pbc.22342

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  9 in total

1.  Inflammatory myofibroblastic tumor of the small bowel mesentery: an unusual cause of abdominal pain and uveitis.

Authors:  Audrey H Choi; Olga L Bohn; Timothy D Beddow; Christopher R McHenry
Journal:  J Gastrointest Surg       Date:  2011-01-05       Impact factor: 3.452

2.  In Reply.

Authors:  Silvia Stacchiotti; Giacomo Giulio Baldi; Paolo Giovanni Casali
Journal:  Oncologist       Date:  2020-10-01

3.  Successful combination chemotherapy for metastatic inflammatory myofibroblastic tumor: A case report.

Authors:  Kyoko Inadomi; Hozumi Kumagai; Kotoe Takayoshi; Hiroshi Ariyama; Hitoshi Kusaba; Akihiro Nishie; Hidetaka Yamamoto; Ken Takase; Mamoru Tanaka; Kosuke Sagara; Yuta Okumura; Kenta Nio; Michitaka Nakano; Shuji Arita; Yoshinao Oda; Koichi Akashi; Eishi Baba
Journal:  Oncol Lett       Date:  2015-09-16       Impact factor: 2.967

4.  The Activity of Chemotherapy in Inflammatory Myofibroblastic Tumors: A Multicenter, European Retrospective Case Series Analysis.

Authors:  Giacomo Giulio Baldi; Mehdi Brahmi; Salvatore Lo Vullo; Elena Cojocaru; Olivier Mir; Michela Casanova; Bruno Vincenzi; Tommaso Martino De Pas; Giovanni Grignani; Maria Abbondanza Pantaleo; Jean Yves Blay; Robin Lewis Jones; Axel Le Cesne; Anna Maria Frezza; Alessandro Gronchi; Paola Collini; Angelo Paolo Dei Tos; Carlo Morosi; Luigi Mariani; Paolo Giovanni Casali; Silvia Stacchiotti
Journal:  Oncologist       Date:  2020-07-12

5.  Relapsed and unresectable inflammatory myofibroblastic tumor responded to chemotherapy: A case report and review of the literature.

Authors:  Yasuhiro Maruyama; Toshirou Fukushima; Daisuke Gomi; Takashi Kobayashi; Nodoka Sekiguchi; Akiyuki Sakamoto; Shigeru Sasaki; Keiko Mamiya; Tomonobu Koizumi
Journal:  Mol Clin Oncol       Date:  2017-08-18

6.  Recurrence of inflammatory myofibroblastic tumor in bladder secondary to prostate treated with laparoscopic radical cystectomy.

Authors:  Hui-hui Zhang; Fan Qi; Xiong-bing Zu; Liang Xu; Long-fei Liu; Lin Qi
Journal:  Med Sci Monit       Date:  2012-08

7.  Neoadjuvant crizotinib in ALK-rearranged inflammatory myofibroblastic tumor of the urinary bladder: A case report.

Authors:  Yoshiyuki Nagumo; Aiko Maejima; Yuta Toyoshima; Motokiyo Komiyama; Kan Yonemori; Akihiko Yoshida; Hiroyuki Fujimoto
Journal:  Int J Surg Case Rep       Date:  2018-05-01

8.  Treatment of Pediatric Inflammatory Myofibroblastic Tumor: The Experience from China Children's Medical Center.

Authors:  Youhong Dong; Kashif Rafiq Zahid; Yidi Han; Pengchao Hu; Dongdong Zhang
Journal:  Children (Basel)       Date:  2022-02-24

9.  Outstanding Response in a Patient With ROS1-Rearranged Inflammatory Myofibroblastic Tumor of Soft Tissues Treated With Crizotinib: Case Report.

Authors:  Danila Comandini; Fabio Catalano; Massimiliano Grassi; Guido Pesola; Rossella Bertulli; Antonio Guadagno; Bruno Spina; Matteo Mascherini; Franco De Cian; Federico Pistoia; Sara Elena Rebuzzi
Journal:  Front Oncol       Date:  2021-06-15       Impact factor: 6.244

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.